Table 1.
Study Characteristics and Outcome Domains Addressed
| Study | Earliest Year of Study Data | Location | Study Design (Follow Up) | Treatment Modality | Sample Size | Patient Demographics | Outcome Domains | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (y) | Female Sex | US Racial/Ethnic Minority | Married* | Physical | Travel | Rec | Freedom | Work | ||||||
| 2011 Ibrahim | 2011 | Malaysia; Multi-Site | Cross-Sectional | HD | 183 | 37.6% aged 51–60 y | 48.5% | N/A | 75.9% | X | X | |||
| PD | 91 | |||||||||||||
| 2010 Johansen | 2005 | US; Multi-Site | Cross-Sectional | HD | 161 | M:60.7 ±14.6; F:59.8 ±13.8 | 45% | M: 28%; F: 36% | N/R | X | ||||
| PD | 1,386 | |||||||||||||
| 2009 Aiyasanon | 2005 | Thailand; Single-Site | Cross-Sectional | HD | 87 | 54.05 | 49.4% | N/A | 66.7% | X | X | X | X | X |
| PD | 23 | 61.39 | 47.8% | N/A | 69.6% | |||||||||
| 2009 Alavi | 2007 | Iran; Single-Site | Cross-Sectional | HD | 63 | 55.3 ± 14.5 | 55.6% | N/A | 81% | X | ||||
| TX | 100 | 40.6 ± 14 | 41% | N/A | 77% | |||||||||
| 2009 Borowiak | 2009 | Poland; Multi-site | Cross-Sectional | HD | 50 | 59.6 ± 13.4 | 56% | N/A | N/R | X | X | |||
| PD | 50 | 58.9 ± 13.2 | 48% | |||||||||||
| 2009 Kontodimoloulos | N/R | Greece; Multi-Site | Cross-Sectional | HD | 642 | 58.1 ± 14.9 | 38.7% | N/A | 65.7% | X | X | |||
| PD | 65 | 58.7 ± 12.9 | 49.2% | N/A | 75.4% | |||||||||
| TX | 167 | 43.7 ± 12.5 | 39.5% | N/A | 63.6% | |||||||||
| 2009 Masuda | 2009 | Japan; Single-Site | Cross-Sectional | HD | 35 | 58.3 ± 14.7 | 31.4% | N/A | N/R | X | ||||
| PD | 26 | 47.5 ± 14.2 | 46.2% | |||||||||||
| 2009 Panagopoulou | 2009 | Greece; Single-Site | Pre-Post Tx | HD | 40 | 57 ± 25 | 50% | N/A | 67.5% | X | ||||
| PD | 36 | 59 ± 25 | 41.6% | N/A | 72.2% | |||||||||
| TX | 48 | 39 ± 20 | 33% | N/A | 47.9% | |||||||||
| 2009 Thong | 1997 | Netherlands; Multi-Site | Cross-Sectional | HD | 1010 | 63.2 ± 13.8 | 43.3% | N/A | 65% | X | ||||
| PD | 543 | 53.3 ± 14.6 | 36.1% | N/A | 73.5% | |||||||||
| 2009 Basok | N/R | Turkey; Single-Site | Cross-Sectional | HD | 24 | 43.08 ± 12.44 | 100% | N/A | N/R | X | X | |||
| PD | 21 | 45.19 ± 8.92 | ||||||||||||
| TX | 20 | 36.45 ± 8.55 | ||||||||||||
| 2007 Apostolou | 2007 | Greece; Single-Site | Cross-Sectional | PD | 26 | 53.6 ± 12.7 | 42.3% | N/A | 65% | X | X | |||
| TX | 20 | 49.2 ± 11.4 | 50% | N/A | 89% | |||||||||
| 2007 Molsted | N/R | Denmark; Single-Site | Cross-Sectional | HD | 71 | 59 ± 16 | 24% | N/A | N/R | X | ||||
| PD | 59 | 59 ± 13 | 44% | |||||||||||
| 2007 Sayin | 2007 | Turkey; Single-Site | Cross-Sectional | HD | 75 | 46.91 ± 15.77 | 28% | N/A | 74.7% | X | X | |||
| PD | 41 | 46.15 ± 15.29 | 61% | N/A | 70.7% | |||||||||
| TX | 20 | 33.15 ± 10.61 | 65% | N/A | 45.0% | |||||||||
| 2006 Juergensen | N/R | US; Multi-Site | Cross-Sectional | HD | 84 | 69.6 ± 13.3 | N/R | 20% | 60% | X | ||||
| PD | 62 | 55 ± 14 | N/R | 17% | 57% | |||||||||
| 2006 Ogutmen | 2003 | Turkey; Multi-Site | Cross-Sectional | HD | 64 | 48.14 ± 15.5 | 42.2% | N/A | 70% | X | X | |||
| PD | 207 | 46.00 ± 13.88 | ||||||||||||
| TX | 302 | 38.22 ± 11.52 | ||||||||||||
| 2005 Barendse | N/R | UK; Single-Site | Cross-Sectional | HD | 35 | 52.8 ± 14.3 | 39% | N/A | 76% | X | ||||
| PD | 57 | |||||||||||||
| TX | 46 | |||||||||||||
| 2005 Kutner | 1996 | US; Multi-Site | Prospective Cohort (1 y) | HD | 455 | 61.2 ± 15.6 | 43.3% | 29.9% | 53.4% | X | ||||
| PD | 413 | 56.1 ± 14.7 | 47.2 % | 19.9% | 65.6% | |||||||||
| 2005 Lee | 2002 | UK; Single-Site | Cross-Sectional | HD | 99 | M: 62.4 ± 14.5; F: 64.0 ± 13.8 | 39% | N/A | N/R | X | X | X | X | |
| PD | 74 | M: 63.5 ± 13.6; F: 53.7 ± 15.5 | 49% | |||||||||||
| TX | 209 | M: 53.6 ± 13.8; F: 51.6 ± 14.1 | 40% | |||||||||||
| 2005 Niu | 2002 | Taiwan; Multi-Site | Cross-Sectional | HD | 80 | 54.7 ± 13.5 | 57.9% | N/A | 72.5% | X | ||||
| PD | 80 | 50.8 ± 12.2 | ||||||||||||
| TX | 80 | 43.3 ± 8.8 | ||||||||||||
| 2005 Van de Ham | N/R | Netherlands; Multi-Site | Cross-Sectional | HD | 16 | 49.0 ± 11.9 | 48.57% | N/A | N/R | X | ||||
| TX | 35 | 52.3 ± 10.4 | 37.5% | |||||||||||
| 2004 Wu | 1995 | US; Multi-Site | Prospective Cohort (1 y) | HD | 698 | 54 | 48% | 37% | 51% | X | X | X | X | X |
| PD | 230 | 59 | 46% | 20% | 67% | |||||||||
| 2003 Manns | 1999 | UK; Single-Site | Prospective Cohort (1 y) | HD | 151 | 62.2 | 13% | N/A | 64% | X | X | |||
| PD | 41 | 56.1 | 80% | N/A | 70% | |||||||||
| 2003 Tomasz | N/R | Poland; Single-Site | Cross-Sectional | HD | 61 | 57.84 ± 11.85 | 39.34% | N/A | 14.75% | X | X | X | ||
| TX | 83 | 43.3 ± 11.73 | 48.19% | N/A | 71.08% | |||||||||
| 2002 Baiardi | 1997 | Italy; Single-Site | Prospective Cohort (16+ mo) | HD | 171 | 61.9 ± 13.4 | 37.4% | N/A | N/R | X | ||||
| PD | 30 | 64.0 ± 15.7 | 36.7% | |||||||||||
| TX | 34 | 44.0 ± 12.0 | 35.3% | |||||||||||
| 2002 Harris | 2002 | UK; Multi-Site | Prospective Cohort (1 y) | HD | 96 | 77.0 ± 4.4 | 38% | N/A | N/R | X | ||||
| PD | 78 | 76.8 ± 4.0 | 30% | |||||||||||
| 2000 Carmichael | N/R | UK; Single-Site | Cross-Sectional | HD | 49 | 57.8 ± 13 | 34.7% | N/A | 71.4% | X | X | |||
| PD | 97 | 57 ± 15 | 40.2% | N/A | 70.1% | |||||||||
| 2000 Diaz-Buxo | 1996 | US; Multi-Site | Cross-Sectional | HD | 16,755 | 59.44 ± 15.28 | 48.22% | 47.07% | N/R | X | X | |||
| PD | 1,260 | 53.45 ± 15.31 | 49.52% | 31.03% | ||||||||||
| 2000 Fujisawa | N/R | Japan; Multi-Site | Cross-Sectional | HD (awaiting TX) | 114 | 45.8 ± 11.9 | 24% | N/A | N/R | X | ||||
| HD (not awaiting TX) | 45.7 ± 6.8 | 31% | ||||||||||||
| TX | 117 | 43.9 ± 9.1 | 57% | |||||||||||
| 1999 Merkus | 1993 | Netherlands; Multi-Site | Cross-Sectional | HD | 120 | 59 ± 16 | 43% | N/A | N/R | X | X | |||
| PD | 106 | 52 ± 14 | 35% | |||||||||||
| 1998 Jofre | 1993 | Spain; Multi-Site | Pre-Post Tx | Pre-TX (HD) | 93 | 45 ± 13.2 | 45% | N/A | N/R | X | ||||
| Post-TX | ||||||||||||||
| 1997 Merkus | 1997 | Netherlands; Multi-Site | Cross-Sectional | HD | 120 | 59.3 ± 15.5 | 43% | N/A | 68% | X | X | |||
| PD | 106 | 52.3 ± 14.0 | 35% | N/A | 79% | |||||||||
| 1996 Curtin | 1996 | US; Multi-Site | Cross-Sectional | HD | 238 | 43 ± 10.6 | 50.1% | 49.6% | N/R | X | ||||
| PD | 30 | |||||||||||||
| 1996 Lok | N/R | Australia; Single-Site | Cross-Sectional | HD | 56 | 42.5 | 37.5% | N/A | N/R | X | ||||
| PD | 8 | |||||||||||||
| 1995 Khan | N/R | UK; Single-Site | Cross-Sectional | HD | 43 | 48.8 | 41.6% | N/A | N/R | X | ||||
| PD | 27 | |||||||||||||
| TX | 102 | |||||||||||||
| 1995 Tell | N/R | US; Single-Site | Cross-Sectional | HD (in-center) | 186 | 54.9 ± 15.3 | 52% | 51% | M: 70%; F: 49% |
X | ||||
| HD (home) | 12 | |||||||||||||
| PD | 58 | |||||||||||||
| 1994 Holley | 1993 | US; Single-Site | Cross-Sectional | HD | 46 | N/R | 53% | 48% | N/R | X | ||||
| PD | 31 | |||||||||||||
| 1992 Pietrabissa | 1982 | Italy; Single-Site | Cross-Sectional | HD | 172 | N/R | N/R | N/A | N/R | X | ||||
| TX | 71 | |||||||||||||
| 1991 Tucker | N/R | US; Single-Site | Cross-Sectional | HD | 22 | 50.4 ± 13.8 | 62% | 72% | 62% | X | ||||
| PD | 29 | 47.1 ± 13.9 | 45% | 27% | 73% | |||||||||
| 1990 Devins | N/R | Canada; Single-Site | Prospective Cohort** (6 wk) | HD (in-center) | 39 | 41 | 42% | N/A | 63% | X | X | |||
| HD (home) | 15 | |||||||||||||
| PD | 11 | |||||||||||||
| TX | 34 | |||||||||||||
| 1990 Koch | N/R | Germany; Multi-Site | Cross-Sectional | HD | 290 | 50.1 | 43% | N/A | 68% | X | ||||
| PD | 68 | 51.8 | 32% | N/A | 79% | |||||||||
| TX | 761 | 43.5 | 41% | N/A | 70% | |||||||||
| 1990 Simmons | 1970 | US; Multi-Site | Cross-Sectional | HD | 83 | Range, 19-–56 | N/R | N/R | N/R | X | X | X | X | |
| PD | 510 | |||||||||||||
| TX (current) | 91 | |||||||||||||
| TX (historical) | 82 | |||||||||||||
| 1989 Bremer | N/R | US; Multi-Site | Cross-Sectional | HD (in-center) | 105 | 57.1 ± 13.4 | 49% | 38% | N/R | X | ||||
| HD (self-care) | 41 | 54.5 ± 11.4 | 46% | 37% | ||||||||||
| HD (home) | 47 | 53.2 ± 12.9 | 49% | 19% | ||||||||||
| PD | 79 | 54.9 ± 13.7 | 35% | 13% | ||||||||||
| TX (first) | 166 | 37.6 ± 11.4 | 42% | 15% | ||||||||||
| TX (failed) | 30 | 36.3 ± 10.3 | 60% | 20% | ||||||||||
| TX (>1) | 21 | 31.2 ± 8.3 | 38% | 10% | ||||||||||
| 1989 Julius | 1984 | US; Multi-Site | Cross-Sectional | HD | 95 | 60% >44 y | 41.1% | 49.5% | 61.1% | X | ||||
| PD | 119 | 60.5% >44 y | 48.7% | 23.3% | 63.0% | |||||||||
| 1988 Wolcott | N/R | US; Multi-Site | Cross-Sectional | HD | 33 | 47.4 ± 15.1 | 30% | 39% | 49% | X | ||||
| PD | 33 | 46.2 ± 14.4 | 30% | 33% | 64% | |||||||||
| 1987 Hart | N/R | US; Multi-Site | Cross-Sectional | HD (in-center) | 347 | 51.9 | 50% | 46.5% | N/R | X | X | |||
| HD (home) | 287 | 47.0 | 35.9% | 13.6% | ||||||||||
| PD | 81 | 49.8 | 54.3% | 16.1% | ||||||||||
| TX | 144 | 37.2 | 43.8% | 16.6% | ||||||||||
| 1985 Evans | N/R | US; Multi-Site | Cross-Sectional | HD (in-center) | 347 | 47.6 | 44.5% | 27.2% | NR | X | ||||
| HD (home) | 287 | 75% | ||||||||||||
| PD | 81 | 75% | ||||||||||||
| TX | 44 | 66.7% | ||||||||||||
Note: Unless otherwise indicated, age is given as mean or mean ± standard deviation; other patient demographics given as percentage.
HD = hemodialysis; PD = peritoneal dialysis; Tx = transplant; M=Male; F=Female; NR = not reported; NA = not applicable; US, United States; UK, United Kingdom; Physical, physical functioning; Rec, recreation;
*
Or Living with a Partner.